8B4E465B-0FD5-4154-824B-1E6B2656FD2F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.943495400788436
- age_years
- 54
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.699
- INTERFERON_GAMMA_RESPONSE+0.686
- ALLOGRAFT_REJECTION+0.645
- IL6_JAK_STAT3_SIGNALING+0.597
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.551
- INFLAMMATORY_RESPONSE+0.550
- MYC_TARGETS_V1+0.549
- TNFA_SIGNALING_VIA_NFKB+0.535
- E2F_TARGETS+0.534
- MYC_TARGETS_V2+0.475
Top 10 suppressed
- KRAS_SIGNALING_DN-0.364
- PANCREAS_BETA_CELLS-0.275
- SPERMATOGENESIS-0.266
- HEDGEHOG_SIGNALING-0.244
- MYOGENESIS-0.160
- ESTROGEN_RESPONSE_EARLY-0.096
- WNT_BETA_CATENIN_SIGNALING-0.092
- BILE_ACID_METABOLISM-0.062
- ESTROGEN_RESPONSE_LATE-0.044
- HEME_METABOLISM+0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934874 | — | — | 0.975 |
| 2 | B7A23896-4182-48D3-A1D9-92C781BF283F | — | — | 0.969 |
| 3 | F873381B-3D15-47B2-9385-080590B316B7 | — | — | 0.968 |
| 4 | C33EDB64-C7B9-49A1-AE73-1D293F8522F6 | — | — | 0.965 |
| 5 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.962 |
| 6 | SRR934932 | — | — | 0.962 |
| 7 | SRR934903 | — | — | 0.962 |
| 8 | SRR934897 | — | — | 0.960 |
| 9 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.960 |
| 10 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.959 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.699 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.686 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.645 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.597 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.551 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.549 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.535 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.534 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.475 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.469 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.466 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| APOPTOSIS | 0.448 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.431 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.425 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.408 | Idelalisib | — uncovered |
| COMPLEMENT | 0.391 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.386 | Inavolisib | — uncovered |